Authorized purpose: SubtlePET V1.0.0 is image-processing software for transfer, storage, and noise reduction of FDG and amyloid PET images, including PET/CT and PET/MR studies.
Clinical role
DICOM image transfer, storage, and noise-reduction preprocessing before professional interpretation.
Images and patients
PET/SPECT/Nuclear Medicine · Whole-body and brain PET imaging regions, including FDG and amyloid PET studies
Key limitation
Keep in mind: The FDA labeling describes image enhancement and noise reduction, not an autonomous diagnosis or treatment decision. Supported tracer, acquisition, reconstruction, and image-review boundaries remain applicable.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: SubtlePET V1.0.0 is image-processing software for transfer, storage, and noise reduction of FDG and amyloid PET images, including PET/CT and PET/MR studies.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole-body and brain PET imaging regions, including FDG and amyloid PET studies Input: DICOM 3.0 FDG and amyloid PET studies, including PET/CT and PET/MR datasets.
Who uses it?Intended users: Radiologists and nuclear medicine physicians.
What does the software produce?Output: Enhanced PET studies with noise reduction forwarded to a destination such as PACS or a workstation.
What is its most important limitation?Key limitation: The FDA labeling describes image enhancement and noise reduction, not an autonomous diagnosis or treatment decision. Supported tracer, acquisition, reconstruction, and image-review boundaries remain applicable.
Clinical takeaway. Clinical role: SubtlePET V1.0.0 is image-processing software for transfer, storage, and noise reduction of FDG and amyloid PET images, including PET/CT and PET/MR studies.
Evidence takeaway. Evidence from the reviewed source record: K182336 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for SubtlePET V1.0.0. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
SubtlePET V1.0.0 is image-processing software for transfer, storage, and noise reduction of FDG and amyloid PET images, including PET/CT and PET/MR studies.
The FDA labeling describes image enhancement and noise reduction, not an autonomous diagnosis or treatment decision. Supported tracer, acquisition, reconstruction, and image-review boundaries remain applicable.
K182336 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for SubtlePET V1.0.0. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K182336 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for SubtlePET V1.0.0. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K182336 FDA evidence package for SubtlePET
DesignFDA 510(k) decision evidence and product verification for the exact submission.
PopulationWhole-body and brain PET imaging regions, including FDG and amyloid PET studies
Scopeexact submission
Tested versionSubtlePET V1.0.0
IndependenceSponsor or vendor study
K182336
FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
No record matched K182336 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM 3.0 FDG and amyloid PET studies, including PET/CT and PET/MR datasets.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes a DICOM node receiving studies from a modality or other DICOM source, processing them, and forwarding the enhanced study to a destination.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Enhanced PET studies with noise reduction forwarded to a destination such as PACS or a workstation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Enhanced PET studies with noise reduction forwarded to a destination such as PACS or a workstation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA package describes a DICOM node receiving studies from a modality or other DICOM source, processing them, and forwarding the enhanced study to a destination.
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
The FDA package describes a DICOM node receiving studies from a modality or other DICOM source, processing them, and forwarding the enhanced study to a destination.
Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
10Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
No evidence was promoted. The records name SubtlePET or PET denoising but do not identify SubtlePET V1.0.0 or K182336; several use additional tracers or unmapped SP1 and SP2 variants outside exact version linkage. The current discovery snapshot contains 10 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price or commercial contract for the exact submission and version was identified.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.
Authorized purpose: uMI Panvivo variants acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, attenuation correction, and the labeled body-region workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Authorized purpose: uMI Panvivo PET/CT acquires anatomical CT and functional PET images of radiopharmaceutical distribution for qualified diagnostic and treatment-planning workflows, including labeled lung-cancer-screening use.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, head and neck, cardiac, and other labeled PET/CT regions
Authorized purpose: BIOGRAPH One with syngo MR XB10 combines metabolic or physiologic PET information with MR anatomy, MR-based attenuation correction, fused alignment, and support for treatment planning and interventions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.